Kalamazoo, Michigan - August 6, 2015 - Stryker Orthopaedics, a division of Stryker Corporation (NYSE:SYK), today announced that its 510(k) submission for the Mako total knee application has received market clearance by the U.S. Food and Drug Administration.
This clearance expands Stryker's current Mako offering of partial knee and total hip applications to provide a comprehensive solution in the robotic reconstructive service line. "The ability to include a Mako total knee application with our market leading Triathlon Total Knee System represents a key milestone in reconstructive surgery," said David K. Floyd, Group President, Orthopaedics. "We are excited about the opportunity to transform orthopaedics by furthering the growth of robotic-arm assisted surgery, and by enhancing the surgeon and patient experience."
Help employers find you! Check out all the jobs and post your resume.
This clearance expands Stryker's current Mako offering of partial knee and total hip applications to provide a comprehensive solution in the robotic reconstructive service line. "The ability to include a Mako total knee application with our market leading Triathlon Total Knee System represents a key milestone in reconstructive surgery," said David K. Floyd, Group President, Orthopaedics. "We are excited about the opportunity to transform orthopaedics by furthering the growth of robotic-arm assisted surgery, and by enhancing the surgeon and patient experience."
Help employers find you! Check out all the jobs and post your resume.
